Drug Approval | November 19, 2022
Eugia Pharma receives USFDA approval for Amphotericin B Liposome for Injection
The product is expected to be launched by Q4 FY23.
The product is expected to be launched by Q4 FY23.
Ketorolac Tromethamine is advised for the short-term management of moderately severe acute pain in adult patients
This is the first injectable product approval from our General Sterile Facility (F-3) which was inspected in August, 2022.
The company currently supplies one product to the US market that contributes low- single digit revenue to Jubilant Pharmova revenue
ADCelerate delivers Phase I appropriate antibody-drug conjugate (ADC) drug substance and drug product for Investigational New Drug (IND) submission
-0001_256_384.jpg){kind=logo}
The eyecirque under eye skin brightening supplement is a unique composition of scientifically proven essential antioxidants, vitamins and minerals
He has over two decades of rich experience in management consulting, advising and transforming leading generic pharmaceutical companies in India and global markets
The approved product has an estimated market size of around US $62 million for the twelve months ending June 2022 according to IQVIA
The approved product has an estimated market size of around US$ 606 million for the twelve months ending June 2022, according to IQVIA.
The 562,000 square feet facility has been recognized as the first and largest integrated insulin manufacturer in Malaysia by MBR
Subscribe To Our Newsletter & Stay Updated
